Objectif The goal of the PEACHI project is to develop simple, affordable and effective vaccine strategies that can be given alone or in combination to prevent hepatitis C virus (HCV), human immunodeficiency virus type 1 (HIV-1) and co-infection. The vaccines are based on novel and powerful viral vectors for in vivo delivery of antigens.The PEACHI Consortium members have employed replication-defective simian adenovirus (ChAd) and modified vaccinia virus Ankara (MVA) vector technology to develop the most immunogenic HCV and HIV-1 vaccines to date. We will assess the safety and immunogenicity of ChAd prime / MVA boost HCV vaccines in a key target group - HIV-positive individuals receiving antiretroviral therapy. These data are essential to support future efficacy studies aiming to assess protection of HIV-infected people from HCV infection. In addition, we will conduct the first phase I clinical studies using two distinct ChAd vectors simultaneously, one hosting an HCV immunogen spanning the entire NS region of HCV and the other, highly conserved HIV-1 sequences. This strategy aims to prime responses against both HCV and HIV-1 antigenic targets concurrently. Similarly, responses will be boosted simultaneously, using MVA vectors that host the respective HIV-1 and HCV immunogens. Finally, recent work by Consortium members has shown that the immunogenicity of ChAd and MVA vectors is markedly improved when the encoded HCV immunogen is fused to mouse or human MHC class II invariant chain. This may be critical to the effectiveness of HCV vaccines in HIV-infected people and will be applicable to vaccine development for other major infectious diseases. Therefore, a large component of this project will be the first assessment of this novel technology in humans. Clinical studies will be complemented by comprehensive laboratory analyses to assess the strength and quality of vaccine-induced T cell responses using state-of-art assays, which will facilitate the discovery of surrogate markers of protective immunity. Champ scientifique natural sciencesbiological sciencesmicrobiologyvirologymedical and health scienceshealth sciencesinfectious diseasesRNA viruseshepatitis Cmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesnatural sciencesmathematicspure mathematicsarithmeticsprime numbers Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Thème(s) HEALTH.2012.2.3.2-1 - Co-infection of HIV/AIDS, malaria, tuberculosis and/or hepatitis Appel à propositions FP7-HEALTH-2012-INNOVATION-1 Voir d’autres projets de cet appel Régime de financement CP-FP - Small or medium-scale focused research project Coordinateur THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Contribution de l’UE € 1 700 285,00 Adresse WELLINGTON SQUARE UNIVERSITY OFFICES OX1 2JD Oxford Royaume-Uni Voir sur la carte Région South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire Type d’activité Higher or Secondary Education Establishments Contact administratif Gill Wells (Ms.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Participants (4) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire REITHERA SRL Italie Contribution de l’UE € 1 645 648,00 Adresse VIA DI CASTEL ROMANO 100 00128 Roma Voir sur la carte Région Centro (IT) Lazio Roma Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Antonella Folgori (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée BORD OSPIDEIL NAOIMH SHEAMUIS Irlande Contribution de l’UE € 480 580,00 Adresse JAMES S STREET 8 DUBLIN Voir sur la carte Type d’activité Research Organisations Contact administratif Colm Bergin (Prof.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée KANTONSSPITAL ST. GALLEN Suisse Contribution de l’UE € 562 300,00 Adresse Rorschacherstrasse 95 9007 St. Gallen Voir sur la carte Région Schweiz/Suisse/Svizzera Ostschweiz St. Gallen Type d’activité Research Organisations Contact administratif Pietro Vernazza (Prof.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée GLAXOSMITHKLINE BIOLOGICALS SA Belgique Contribution de l’UE Aucune donnée Adresse RUE DE L INSTITUT 89 1330 Rixensart Voir sur la carte Région Région wallonne Prov. Brabant Wallon Arr. Nivelles Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Philippe Denoel (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée